J. Goldman & Co LP purchased a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 300,131 shares of the company's stock, valued at approximately $1,086,000. J. Goldman & Co LP owned about 0.36% of Atyr PHARMA as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of the stock. Jefferies Financial Group Inc. bought a new position in Atyr PHARMA during the 4th quarter worth $201,000. Group One Trading LLC bought a new position in Atyr PHARMA during the 4th quarter worth $26,000. Balyasny Asset Management L.P. bought a new position in Atyr PHARMA during the 4th quarter worth $160,000. Bank of America Corp DE bought a new position in Atyr PHARMA during the 4th quarter worth $330,000. Finally, Alyeska Investment Group L.P. bought a new position in Atyr PHARMA during the 4th quarter worth $4,628,000. 61.72% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on ATYR shares. HC Wainwright reiterated a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a report on Friday, March 14th. Leerink Partners started coverage on Atyr PHARMA in a report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target for the company. Finally, Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $18.60.
Read Our Latest Analysis on ATYR
Atyr PHARMA Stock Down 8.5%
Shares of ATYR traded down $0.28 during trading hours on Wednesday, hitting $3.03. The stock had a trading volume of 2,014,716 shares, compared to its average volume of 915,739. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The firm has a 50 day simple moving average of $3.27 and a 200-day simple moving average of $3.40. The firm has a market capitalization of $269.68 million, a P/E ratio of -3.22 and a beta of 0.79. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. Sell-side analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.
Atyr PHARMA Profile
(
Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Articles
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
